On January 23rd, CureX recently announced that 20% of the sales of its TRC-T products for the treatment of malignant synovial sarcoma will be used to buy back CUX and destroy it. This operation marks that CureX has further strengthened the value and market stability of CUX tokens while promoting the application of its biotech products. In the first round of repurchase, CureX purchased 100 SOL and destroyed 4259,993 CUX tokens. CureX promises to continue to use a part of its product revenue to buy back and destroy CUX tokens in the future. CureX will continue to work on developing advanced biotechnology products to solve more disease problems and bring changes to the global healthcare industry through innovative blockchain technology. At the same time, CureX has airdropped the project 142pact, bringing a new cooperation experience.